OFFICERS, DIRECTORS AND ADVISORS
Chief Executive Officer
Mr. Mark Kyle has recently been retained as the Company’s Chief Executive Officer. Prior to joining the Company, Mr. Kyle served as managing director of Encore Kinetics Group, an Austin, Texas based syndicator of financial investment opportunities in the energy investment sector.
From 2010 to 2012, Mr. Kyle was managing director of Applied Quantitative Solutions, a company engaged in the development of a process focused on financial investments. From 2003 to 2001 Mr. Kyle was president and a founder of Paragon Specialty Healthcare, a company engaged in delivering sterile compounded injectables to health care facilities nationwide. During his tenure Mr. Kyle participated in the establishment of a network protocol in which an independent compounding pharmacy can provide necessary sterile injectable directly to acute care facilities and coordinated pharmacy and marketing to a well-organized unit.
From 1993 to 2005, Mr. Kyle was president and a founder of Paragon Scientific Corporation, a company engaged in the worldwide distribution of bio-pharmaceuticals, surgery and medical disposables to human and animal healthcare facilities and a leader in distribution of hemophilia products; and successfully launched multiple new pharmaceuticals. The company was listed as fastest growing independent company in Austin, Texas and, under Mr. Kyle’s direction, founded “A Happy Face” a non-profit dedicated to offering scholarships to underprivileged children with hemophilia to help them attend summer camps.
From 1986 to 1993 Mr. Kyle was Senior Vice President and a co-founder of FFF Enterprises, a company engaged in the worldwide distribution of medical latex gloves, bio-pharmaceuticals and medical disposables to human and animal healthcare facilities. FFF Enterprise was the first distribution company to work with Group Purchasing Organizations on a direct basis and created the Standard of Care in Latex Exam gloves for the Dialysis market.
Dr Vasilis "Bill" Paspaliaris
Executive Director, Chairman and President
Dr. Paspaliaris has worked at and consulted for a number of pharmaceutical and biotech companies globally. Due to his innovation he has been the founder and director of seven biotech companies since 2000.
In early 2006, he founded Adistem, Ltd in Hong Kong. After finishing his doctorate in pharmacology/endocrinology in 1993 at St Vincent’s Institute of Medical Research at the University of Melbourne, he completed his post-doctoral fellowship at Pfizer Central Research in Connecticut. During this time he was given two scholarships from the Australian Federal Government, and the National Health and Medical research Council of Australia and two young investigators awards in osteoporosis research from the Australian and New Zealand Bone and Mineral Society, and the International Society for Bone and Mineral Research. After doing his clinical training in Greece, he worked in combat trauma medicine in Africa where he remained and performed humanitarian work.
In 2008, Dr. Paspaliaris received an Appreciation Award from the American Association of Clinical Endocrinologists for his groundbreaking work on adipose-derived stem cells in Type II diabetes and two certificates of appreciation from the American Academy of Anti-Aging Medicine on his stem cell research and an investigators award from the Hellenic Thoracic Society.
Dr. Paspaliaris has published over 20 papers, holds over 5 patents and given lectures in a variety of medical fields, mostly in stem cell medicine. He is currently a Faculty Member for the Masters degree program in Clinical Pharmacology and Therapeutics at Democritus University Medical School and the University of Crete in Greece. He is a member of the World Society of Interdisciplinary Anti-aging Medicine, the Australian Military Medicine Association and Latin American Stem Cell Society, a Fellow of the Philippine Society of Stem Cell Medicine, a Diplomat of the American Board of Regenerative Medicine, a Fellow of the American Academy of Regenerative Medicine and a Fellow of the Royal Society of Medicine (UK).
Executive Director and Chief Operations Officer
Mr. Milonas was educated in Melbourne, Australia, initially at La Trobe University, where he completed a Bachelor Degree (Social Sciences) after undertaking studies across a diverse range of disciplines, including Science, Law and Arts, and later at Monash University, where he completed Pharmaceutical Industry specific Post Graduate (APMA CEP) qualifications.
His career followed his passion, Health Care, and for the last 20 years he has worked in the Pharmaceutical Industry, developing extensive knowledge and experience in Sales, Marketing and Management across a number of therapeutic areas and medical sectors such as: Biotechnology, Cosmetic Medicine, Ophthalmology, Women’s Health, Surgical & Capital Equipment, Gastroenterology, CNS, Hospital, Aged Care and Pharmacy.
From his early beginnings as a Sales Representative, on the front line, to Business Development, and National Sales & Marketing Management, all the way through to Chief Operating Officer and Director, Peter has a complete understanding, and perspective, of the intricate world of the Health Care and Pharmaceutical business. His expertise in this area has been acquired over 2 decades of working for some major Health Care/Pharmaceutical organizations in the industry including: WYETH AYERST and LEDERLE LABORATORIES, international pharmaceutical company, specializing in areas such as, Women’s health, Gastroenterology, Vaccine and CNS markets; ALCON LABORATORIES & SURGICAL, an international company specializing in the discovery, development, manufacture and marketing of surgical devices, vision care products and ophthalmic pharmaceuticals; and AUSTRALASIAN MEDICAL & SCIENTIFIC established with the aim of providing the Australian scientific and medical markets with a range of leading edge products from around the world.
In the last two years Peter has been instrumental in the development of the business around the incorporated technologies into Adilyfe as he was working as the Business Development Manager of Adistem, General Manager of Paspa Pharmaceuticals, Director and Vice president of Black Arrow Biotech and Chief Operating Officer of Nereen Healthcare.
Dr Michael Hutchinson
A leading practitioner in stem cell therapy, Dr. Mike Hutchinson, D.V.M., is a highly sought after speaker at national and international veterinary conferences on the uses of animal stem cells.
Dr. Mike has performed more than 1000 Adipose-Derived Stem Cell procedures on dogs, cats, horses, camels and a bird, among his 20,000 surgeries in 31 years of practicing veterinary medicine.
Shortly after the terrorism attacks of 9/11, Dr. Mike was trained in the economic consequences of bioterrorism and agro-terrorism through funding from the Centers for Disease Control and Prevention. He also has co-authored a study on Serotypes of Bovine Astrovirus, published in the Journal of Clinical Microbiology.
A veteran of more than 250 media interviews, Dr. Mike is a regular guest veterinarian on KDKA-TV’s “Pittsburgh Today Live.” He recently concluded his the weekly guest host of “Animal General with Dr. Mike” on powerhouse radio station KDKA-AM. In 2009, he was presented with the “Rising Star Award” from the Veterinary News Network.
For volunteering his time and experience, Dr. Mike has received numerous awards from breed clubs, the Cat Fanciers’ Association and Pioneers for Animal Welfare Society (PAWS). He was named to an honorary position on the Board of Directors of the prestigious Theodore Roosevelt Sanctuary for his work with wildlife and received a distinguished service award for 12 years (1986-1998) as veterinarian for the Nassau County, New York Mounted Police Force.
Dr. Mike graduated from the Pennsylvania State University in 1981 with a degree in Animal Bioscience, and earned his D.V.M. degree from the Iowa State University School of Veterinary Medicine in 1986. Owner of Animal General of Cranberry, near Pittsburgh, he is married and the father of five children.
Tithon Biotech Chief Financial Officer
Richard F. Schmidt, CPA has recently been retained to serve as the Company’s Chief Financial Officer pursuant to a retainer agreement in which Mr. Schmidt will provide such services on a part-time basis, until the Company has obtained sufficient funding and is engaged in a level of business operations requiring his full time provision of services.
Mr. Schmidt currently serves as a Controller at Senior Aerospace Ketema, where he leads all financial and accounting functions. From 2011 to 2013 Mr. Schmidt served as the Chief Financial Officer of Z Microsystems, San Diego where he led all financial and accounting functions including, audit, tax, insurance, banking and human resources.
From 2005 to 2011 Mr. Schmidt served as the Chief Financial Officer of Volvo Construction Equipment and Services. From 1999 to 2005 Mr. Schmidt served as the Chief Financial Officer of Cybertel Communications Corporation, where he not only managed all financial and accounting functions, but was directly responsible for the preparation and filing of all reports under US Federal and State securities laws.
From 1994 to 1999 Mr. Schmidt served as the Chief Financial Officer of Iseki Inc. where he was responsible for timely reporting to the public parent company in Japan. As Iseki’s CFO, Mr. Schmidt managed all aspects of audit, tax and human resources and conducted project analysis with the sales team to determine profitability and return on investment.
Further, at Iseki, Mr. Schmidt served as a liaison on operational aspects for Japanese nationals serving as president. From 1986 to 1994 Mr. Schmidt was engaged in public accounting with the firm Coopers & Lybrand. Mr. Schmidt is a Certified Public Accounts, and received a B.A. degree from Gonzaga University, Spokane, Washington.
Tithon Biotech Director of Legal and Compliance
Mr. Strawn, over the past 35 years, has engaged in the practice of securities law, as an attorney, and has participated, as a private investor, in various business ventures. As a practicing attorney, Mr. Strawn has represented: registered broker dealers, venture capital investors, public reporting companies, issuers in private and IPO transactions, private and public companies in acquisition transactions, domestic broker-dealers and foreign broker-dealers engaged in cross boarder business and has participated in the development of an online Internet based trading system providing both order execution in trading securities and an online investment banking platform. Mr. Strawn has worked extensively in offshore financial markets and participated in the development of cross border PATRIOT Act compliance programs.
As a private investor, Mr. Strawn has participated in the strategic planning, development and funding of start-up companies, and acquisition and collaboration transactions involving early stage growth and mid-cap companies engaged in various industries, including: mining and natural resources, healthcare, biosciences, financial services, telecommunication, construction and transportation.
Mr. Strawn graduated from Portland State University, summa cum laude, with a degree in finance in 1977 and from the University of Arizona-Arizona School of Law, with honors, with a Juris Doctorate degree in 1980. Mr. Strawn resides in San Diego, California.